Final rule 2025-18082
Microbiology Devices; Reclassification of Antigen, Antibody, and Nucleic Acid-Based Hepatitis B Virus Assay Devices
The Food and Drug Administration (FDA) is issuing a final order reclassifying qualitative hepatitis B virus (HBV) antigen assays (product code LOM), HBV antibody assays (product code LOM), and quantitative HBV nucleic acid-based assays (product code MKT), all of which are postamendments class III devices, into class II (special controls), subject to premarket notification. FDA is also establishing the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of these device types.
Source-supplied record
Document details
- Document number
- 2025-18082
- Published
- Sep 18, 2025
- Effective
- Oct 20, 2025
- Comments close
- Not supplied
- Federal Register citation
- 90 FR 44969
Docket identifiers
- Docket No. FDA-2024-N-3533
CFR references
- Title 21, part 866